 In May 2017, the company announced it would acquire True North Therapeutics for $825 million, strengthening Bioverativ's pipeline with the acquisition of TNT009 – a treatment for cold agglutinin disease.In January 2018, Sanofi announced that it would acquire the business, for $11.6 billion.The following is an illustration of the company's major mergers and acquisitions and historical predecessors